AFYA Afya

Afya Limited Announces PEBMED’s Acquisition

Afya Limited Announces PEBMED’s Acquisition

NOVA LIMA, Brazil, July 21, 2020 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA) today announced the acquisition of 100% of the total share capital of PEBMED, through its wholly-owned subsidiary Afya Participações S.A.

PEBMED offers content and clinical decision applications aiming a better performance of the healthcare professional, through its products:

  • WhiteBook: a mobile and web application software that helps doctors and medical students to make faster and more accurate clinical decisions on a daily practice. It provides medical calculators, images and updated content, including prescriptions, conducts, clinical scores, procedures, lab exams, and others, for more than 28 specialties. WhiteBook’s revenue represents more than 95% of PEBMED’s total revenue and currently has 165,000 monthly active users.

     
  • Nursebook, a mobile application software that helps nurses to make accurate clinical decisions. This product also provides medical calculators, procedures and updated content software designed to help nurses all over Brazil. This product was launch on the third quarter of 2019 and currently has 20,000 monthly active users.

     
  • Portal PEBMED: a website that offers free references, perspectives and updates on medical news and scientific publications. The website has over 4,000,000 visitors per month and 900,000 returning visitors.  

"With the integration of PEBMED into our platform, Afya will continue to expand our offerings for the medical professionals now focusing in the interaction with the patient," said Virgílio Gibbon, Afya’s CEO. “With this acquisition, Afya will strengthen its position in the medical field and expand our digital platform.”

"We founded PEBMED because we saw hundreds of doctors facing unprecedented circumstances and we wanted to help then in these difficult situations," said Bruno Lagoeiro, CEO of PEBMED. "Becoming part of the Afya platform will allow us to accelerate software development, reach more doctors and students across the country and fulfill our goal to help transform Brazilian health through the decisions that nurses and physicians make every day."

The acquisition will enable Afya to enter into a new business segment and will contribute to the development and expansion of Afya Digital increasing our monthly active users and bringing active physicians to our platform.

The net purchase price was R$132.9 million, with the assumption of estimated net debt of R$7.1 million, of which: (i) 86.8% was paid in cash, and (ii) 13.2% was paid in Afya’s stock. The price multiple is equivalent to 4x PEBMED’s annual recurring revenue.

Afya’s management team will host a conference call with investors June 21, 2020, 11:00 am EDT.

Investors may listen to the conference call (ID: AFYA) by dialing +1 (844) 204-8942 or +1 (412)-717-9627 for US Numbers and (11) 3181-8565 for BR Numbers. A live and archived webcast of the call will be available on the Investor Relations section of the Company’s website at /. 

About Afya

Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners from the moment they join us as medical students through their medical residency preparation, graduation program, and continuing medical education activities.

Contact: Investor Relations:

EN
21/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Afya

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Lockout Rally in Full Swing Continuing the trend from last week's U.S. Macro Vision (4/29/25), we are seeing more and more signs that lead us to believe the S&P 500 (SPX) made a major bottom at 4800-4820, which is where we initially discussed in our 4/8/25 Compass to look for a local bottom to develop. As a result, we have been short-term bullish since our 4/22/25 Compass, when we noted that the SPX was testing 5100-5120 support, a potential bounce spot and a level to trade long against. With t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommen...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Breakouts Proliferate; Bullish Outlook Intact The S&P 500, Nasdaq 100, and DJI are breaking out to new all-time highs following 3-week consolidations, while the small-cap Russell 2000 (IWM), mid-cap S&P 400 (IJH), Vanguard Extended Market ETF (VXF), and countless other Sectors/industries are breaking out from 3-week bullish falling wedge/flag patterns. This is classic bull market behavior. Considering market dynamics remain healthy, this is all evidence that supports our ongoing bullish outlook...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Year-End Rally to Continue? The broad equity market has been on an absolute tear since we discussed in our 10/31/23 Compass how risk/reward favored buyers as key supports were being tested, including 4165 on the S&P 500, $162-$163 on the Russell 2000 (IWM), and $350 on the Nasdaq 100 (QQQ). Furthermore, we discussed in our 11/7/23 Compass our belief that this was more than just another counter-trend rally, and that it is likely the start of a significant year-end rally. We also reiterated our b...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bullish Breadth Divergences Persist The S&P 500 is just below 4165-4200 support, and the Nasdaq 100 (QQQ) is just below $350-$355 support. Given they were only 1%-1.5% below these supports at last week's lows, we cannot call them "decisive" breakdowns quite yet. Regardless, these levels are now resistance (in addition to the 200-day MA on SPX), and they are important lines-in-the-sand moving forward. We cannot be bullish if the SPX and QQQ are below the aforementioned levels, but it would be bu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch